Proposed response criteria for patient evaluation in BPDCN
| BPDCN compartment of disease* . | Evaluation method . | Response criteria disease area . | Year/reference . | Notes . |
|---|---|---|---|---|
| Cutaneous (skin) | mSWAT | CTCL | 2011/51 | mSWAT = modified severity weighted assessment tool |
| Blood/bone marrow | CBC; bone marrow aspiration/biopsy | AML | 2003/52 | BPDCN can transform to AML, so always confirm diagnosis with expert pathology team |
| Lymph node | PET/CT; CT | NHL | 2014/53 | Can also image other visceral/extramedullary sites |
| BPDCN compartment of disease* . | Evaluation method . | Response criteria disease area . | Year/reference . | Notes . |
|---|---|---|---|---|
| Cutaneous (skin) | mSWAT | CTCL | 2011/51 | mSWAT = modified severity weighted assessment tool |
| Blood/bone marrow | CBC; bone marrow aspiration/biopsy | AML | 2003/52 | BPDCN can transform to AML, so always confirm diagnosis with expert pathology team |
| Lymph node | PET/CT; CT | NHL | 2014/53 | Can also image other visceral/extramedullary sites |
BPDCN response criteria based on Pemmaraju et al.44 CR equals no detectable disease in all 3 compartments.
CBC, complete blood count; CT, computed tomography; CTCL, cutaneous T-cell lymphoma; NHL, non-Hodgkin lymphoma; PET, positron emission tomography.
CRc equals no detectable disease noted in nonskin organs, with gross decrease in cutaneous lesions; evidence of microscopic residual skin disease.